PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Author: Business Wire
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
SAN DIEGO–(BUSINESS WIRE)–LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people wit…
Senior Ophthalmology Executive Thomas A. (Tom) Dunlap Joins WaveFront Dynamics Inc. as an Independent Member of the Board of Directors to Support the Company’s Ongoing Commercialization and Broader Strategic Initiatives
ALBUQUERQUE, N.M.–(BUSINESS WIRE)–WaveFront Dynamics Inc., a pioneer in wavefront sensing technology perfecting visual performance, welcomes Tom Dunlap to the Board of Directors.
GenSight Biologics confirme l’efficacité et la sécurité durables des injections bilatérales de LUMEVOQ® quatre ans après une administration unique
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible au PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les …
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Tilak Healthcare Strengthens Its Leadership Team
PARIS–(BUSINESS WIRE)–Tilak Healthcare, a leading company in digital health for the monitoring of chronic eye diseases, announces the appointment of three experts to support the leadership team, currently composed of Edouard Gasser (CEO & co-foun…
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more t…
Nordic Group B.V., par l’intermédiaire de sa filiale Nordic Pharma, Inc. (U.S.), nomme un chirurgien oculoplastique de renom, John P. Fezza, MD, au sein de son conseil consultatif médical
BERWYN, Pennsylvanie–(BUSINESS WIRE)–Nordic Pharma, Inc., une filiale de Nordic Group B.V., annonce aujourd’hui que l’éminent chirurgien oculoplastique John P. Fezza, MD, intégrera son conseil consultatif médical (MAB) aux États-Unis, qui comprend Er…
OneLegacy Partnered with Danny Trejo and Trejo Music to Host SOULDIEZ Concert Featuring Talented Artists, Lowriders, Trejo’s Tacos and More
LOS ANGELES–(BUSINESS WIRE)–OneLegacy Inspires Hollywood partnered with Danny Trejo and Trejo Music to present SOULDIEZ, a music concert that took place at the OneLegacy’s Headquarters in Azusa with the goal of sharing the power of music with the cri…
Nordic Group B.V. ernennt über die Tochtergesellschaft Nordic Pharma, Inc. (USA) den anerkannten Augenchirurgen John P. Fezza, MD zum Mitglied des Medical Advisory Board
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc., eine Tochtergesellschaft der Nordic Group B.V., hat heute bekannt gegeen, dass der bekannte okuloplastische Chirurg John P. Fezza, MD zum Mitglied ihres U.S. Medical Advisory Board (MAB) ernannt wurde….
Riassunto: Nordic Group B.V., tramite la sua affiliata Nordic Pharma, Inc. (U.S.), nomina il rinomato chirurgo oculoplastico John P. Fezza, MD, membro del Consiglio di consulenza medica
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc., un’affiliata di Nordic Group B.V. oggi ha annunciato che l’eminente chirurgo oculoplastico John P. Fezza, MD, entrerà a far parte del Consiglio di consulenza medica che include Eric Donnenfeld, MD (New…
Resumen: Nordic Group B.V. a través de su filial Nordic Pharma, Inc. (EE. UU.), nombra al prestigioso cirujano oculoplástico John P. Fezza, miembro de su Junta asesora médica
BERWYN, Pensilvania–(BUSINESS WIRE)–Nordic Pharma, Inc, filial de Nordic Group B.V., ha anunciado hoy que el prestigioso cirujano oculoplástico John P. Fezza, formará parte de su Junta asesora médica (MAB, por sus siglas en inglés) en Estados Unidos….
Samenvatting: Via haar dochteronderneming Nordic Pharma, Inc. (U.S.) benoemt Nordic Group B.V. de vermaarde oculoplastische chirurg John P. Fezza, MD, tot lid van haar Medische Adviesraad
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc., een dochteronderneming van Nordic Group B.V., maakte vandaag bekend dat de eminente oculoplastische chirurg John P. Fezza, MD, zal zetelen in haar MAB in de V.S. (Medical Advisory Board = Medische Advi…
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Appoints Renowned Oculoplastic Surgeon, John P. Fezza, MD to Its Medical Advisory Board
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc. announced today that eminent oculoplastic surgeon John P. Fezza, MD will serve on its U.S. Medical Advisory Board (MAB).
OcuTerra Announces Topline Data from Phase 2 DR:EAM Trial Evaluating Nesvategrast (OTT166 5%) for Patients with Diabetic Retinopathy
BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics announces topline data from the Phase 2 DR:EAM clinical trial.
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Company has entered into an agreement to sell its DERMAd…
Surface Ophthalmics Announces New Leadership with Richard Lindstrom, MD, and Renewed Vision for Addressing Critical Unmet Needs of Dry Eye Syndrome Patients
PLEASANTON, Calif.–(BUSINESS WIRE)–Surface Ophthalmics, a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder &…
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
National Vision Awards Trio of Optometry Students $12,500 in Ninth Annual Scholarship Program
DULUTH, Ga.–(BUSINESS WIRE)–National Vision, Inc., one of the largest optical retail companies in the U.S. providing quality, affordable eye care and eyewear, announced today the winners of its ninth annual scholarship program, fueling the success of…
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment …